ESH AL 2018 | Improving the activity of BH3 mimetic venetoclax: a case study
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Melbourne, Australia, discusses clinical trials investigating the effect of BH3 mimetic drugs, such as venetoclax, on acute myeloid leukemia (AML). Current studies are trying to improve the activity of venetoclax in combination with low-dose chemotherapy and hypomethylating agents in patients with poor risk FLT3, DNMT3A or IDH mutations to produce a longer, more sustainable remission. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Get great new content delivered to your inboxSign up